A Phase-1 Study Evaluating the Safety, Pharmacology and Preliminary Activity of MM-310 in Patients With Solid Tumors

Trial Profile

A Phase-1 Study Evaluating the Safety, Pharmacology and Preliminary Activity of MM-310 in Patients With Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Dec 2017

At a glance

  • Drugs MM 310 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Merrimack Pharmaceuticals
  • Most Recent Events

    • 10 May 2017 According to a Merrimack Pharmaceuticals media release, the company expects to report safety data and a recommended Phase 2 dose from this study in 2018.
    • 23 Mar 2017 According to a Merrimack Pharmaceuticals media release, the company expects to report data from part one of the study in 2018.
    • 23 Mar 2017 According to a Merrimack Pharmaceuticals media release, first patient has been enrolled in the trial. Five sites are currently expected to participate in this study. The first patient was dosed at Honor Health in Scottsdale, AZ.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top